8,733 Shares in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Purchased by MetLife Investment Management LLC

MetLife Investment Management LLC acquired a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 8,733 shares of the company’s stock, valued at approximately $135,000.

Separately, BNP Paribas Financial Markets purchased a new stake in shares of Artiva Biotherapeutics in the third quarter valued at approximately $42,000.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ:ARTV opened at $11.77 on Tuesday. Artiva Biotherapeutics, Inc. has a 12-month low of $9.68 and a 12-month high of $17.31. The business’s 50-day simple moving average is $12.41.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). On average, sell-side analysts forecast that Artiva Biotherapeutics, Inc. will post -4.68 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on ARTV. Wedbush reissued an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Friday, August 30th. Cantor Fitzgerald began coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They set an “overweight” rating and a $23.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. TD Cowen initiated coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a “buy” rating on the stock. Finally, Jefferies Financial Group started coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued a “buy” rating and a $21.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $21.25.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.